Palonestron, Granisetron and Ramosetron for Prevention of Postoperative Nasea and Voming After Laparoscopic Abdominal Surgery
We compared the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT3 antagonist, granisetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after laparoscpic abdominal surgery.
This study was conducted to determine the efficacy of three 5-HT3 receptor antagonists in the prevention of PONV for laparoscopic surgery in patients receiving PCA IV.
Female Patients Undergoing Laparoscopic Abdominal Surgery
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
- severity of nasea [ Time Frame: immediated postop to 48hrs after surgery ] [ Designated as safety issue: No ]
- frequency of rescue drug needed [ Time Frame: postop to 48hrs after surgery ] [ Designated as safety issue: No ]
|Study Start Date:||December 2011|
|Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Patient recieving Palonosetron/granisetron and ramosetron
Please refer to this study by its ClinicalTrials.gov identifier: NCT01752374
|Korea, Republic of|
|Incheon, Incehon, Korea, Republic of, 405-760|